An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.